Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 19 studies | 40% ± 21% | |
peripheral blood | 11 studies | 23% ± 6% | |
eye | 7 studies | 45% ± 18% | |
lung | 6 studies | 38% ± 12% | |
kidney | 5 studies | 21% ± 5% | |
bone marrow | 4 studies | 23% ± 8% | |
heart | 4 studies | 39% ± 4% | |
adipose | 4 studies | 32% ± 9% | |
liver | 3 studies | 36% ± 15% | |
intestine | 3 studies | 18% ± 0% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3418.74 | 1445 / 1445 | 100% | 18.50 | 183 / 183 |
intestine | 100% | 3310.82 | 966 / 966 | 100% | 10.91 | 527 / 527 |
ovary | 100% | 3611.62 | 180 / 180 | 100% | 13.87 | 430 / 430 |
prostate | 100% | 3509.87 | 245 / 245 | 100% | 13.31 | 502 / 502 |
breast | 100% | 2887.92 | 459 / 459 | 100% | 12.94 | 1117 / 1118 |
lung | 100% | 3422.17 | 577 / 578 | 100% | 11.94 | 1155 / 1155 |
thymus | 100% | 3850.61 | 653 / 653 | 100% | 13.31 | 603 / 605 |
stomach | 100% | 2638.04 | 359 / 359 | 100% | 14.25 | 285 / 286 |
uterus | 100% | 3631.67 | 170 / 170 | 100% | 10.70 | 457 / 459 |
bladder | 100% | 4114.24 | 21 / 21 | 99% | 8.60 | 501 / 504 |
skin | 100% | 3118.75 | 1809 / 1809 | 99% | 9.78 | 466 / 472 |
kidney | 100% | 1647.40 | 89 / 89 | 99% | 10.38 | 889 / 901 |
pancreas | 98% | 1440.72 | 323 / 328 | 99% | 11.94 | 177 / 178 |
brain | 96% | 1617.75 | 2541 / 2642 | 100% | 11.94 | 705 / 705 |
adrenal gland | 100% | 2585.00 | 258 / 258 | 93% | 7.11 | 213 / 230 |
liver | 98% | 991.55 | 222 / 226 | 88% | 5.07 | 359 / 406 |
adipose | 100% | 2898.54 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3903.82 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 10.82 | 29 / 29 |
spleen | 100% | 3313.12 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 11.44 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.17 | 1 / 1 |
muscle | 100% | 2097.60 | 802 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 4414.85 | 921 / 929 | 0% | 0 | 0 / 0 |
heart | 95% | 1651.56 | 814 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 73% | 3.51 | 58 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0065004 | Biological process | protein-DNA complex assembly |
GO_0016925 | Biological process | protein sumoylation |
GO_1904377 | Biological process | positive regulation of protein localization to cell periphery |
GO_0007283 | Biological process | spermatogenesis |
GO_0045444 | Biological process | fat cell differentiation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0032436 | Biological process | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0006974 | Biological process | DNA damage response |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0051152 | Biological process | positive regulation of smooth muscle cell differentiation |
GO_0008542 | Biological process | visual learning |
GO_0033235 | Biological process | positive regulation of protein sumoylation |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0007259 | Biological process | cell surface receptor signaling pathway via JAK-STAT |
GO_0042127 | Biological process | regulation of cell population proliferation |
GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
GO_0005856 | Cellular component | cytoskeleton |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0034399 | Cellular component | nuclear periphery |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0019789 | Molecular function | SUMO transferase activity |
GO_0140297 | Molecular function | DNA-binding transcription factor binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0061665 | Molecular function | SUMO ligase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PIAS1 |
Protein name | Cell proliferation-inducing protein 23 (Protein inhibitor of activated STAT, 1, isoform CRA_b) E3 SUMO-protein ligase PIAS1 (EC 2.3.2.-) (DEAD/H box-binding protein 1) (E3 SUMO-protein transferase PIAS1) (Gu-binding protein) (GBP) (Protein inhibitor of activated STAT protein 1) (RNA helicase II-binding protein) Protein inhibitor of activated STAT 1 Protein inhibitor of activated STAT1 |
Synonyms | hCG_23811 DDXBP1 |
Description | FUNCTION: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Sumoylates PML (at'Lys-65' and 'Lys-160') and PML-RAR and promotes their ubiquitin-mediated degradation. PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation. Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity). Mediates the nuclear mobility and localization of MSX1 to the nuclear periphery, whereby MSX1 is brought into the proximity of target myoblast differentiation factor genes (By similarity). Also required for the binding of MSX1 to the core enhancer region in target gene promoter regions, independent of its sumolyation activity (By similarity). Capable of binding to the core enhancer region TAAT box in the MYOD1 gene promoter (By similarity). .; FUNCTION: (Microbial infection) Restricts Epstein-Barr virus (EBV) lytic replication by acting as an inhibitor for transcription factors involved in lytic gene expression . The virus can use apoptotic caspases to antagonize PIAS1-mediated restriction and express its lytic genes . . |
Accessions | H3BUL7 Q1XBU8 ENST00000249636.11 [O75925-1] A4ZVS7 ENST00000545237.1 [O75925-2] ENST00000564915.5 ENST00000563996.1 A4ZVS8 O75925 H3BS65 ENST00000562190.1 H3BSI8 |